Download PDF
Pharmacopsychiatry 2011; 44(3): 87-95
DOI: 10.1055/s-0031-1271682
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Quetiapine in Adolescents with Non-Affective Psychotic Disorders: An Open-Label Trial

L. Holzer1 , U. Preuss2 , L. Baumgartner2 , L. Jaugey1 , S. Urben1 , O. Halfon1 , P. Baumann3
  • 1Service Universitaire de Psychiatrie de l’Enfant et de l’Adolescent (SUPEA), CHUV Lausanne, Switzerland
  • 2Child and Adolescent Psychiatry and Psychotherapy (UPD), University Berne, Switzerland
  • 3Department Psychiatry (DP), CHUV Prilly-Lausanne, Switzerland
Further Information

Publication History

received 05.09.2009 revised 04.11.2010

accepted 04.11.2010

Publication Date:
11 February 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: There is a need for more studies on the clinical effectiveness, tolerability and pharmacokinetics of atypical antipsychotics in adolescents with psychotic disorders, as this represents a vulnerable and difficult population to treat. According to recent concerns regarding disabling side effects of antipsychotics, particularly weight gain, further monitoring of their safety profiles is needed. This situation prompted the authors to carry out an investigation on the clinical effectiveness of quetiapine in psychotic adolescents.

Methods: 23 adolescents (13–18 years old) with psychotic disorders participated in a 12-week open label trial, including 6 visits assessing clinical efficacy, tolerability and safety of quetiapine (50–750 mg daily).

Results: Adolescents were treated with lower doses compared to adults. Significant decreases in CGI and PANSS total scores were observed after both 4 and 12 weeks of quetiapine treatment compared to baseline. Sedation was the main adverse effect, but medication was generally well tolerated. Irregular compliance, (as assessed by pill counts, a questionnaire and by plasma quetiapine concentration monitoring), and alcohol and/or cannabis consumption were factors identified in this study which add to the difficulty in treating this population.

Discussion: The results of the present study help to consolidate evidence of the usefulness of quetiapine as a treatment for adolescents with psychotic disorders. However, this study also highlights the issues encountered in treating this group, including the presence of comorbidities such as drug abuse.

References

  • 1 van OSJ, Kapur S. Schizophrenia.  Lancet. 2009;  374 (9690) 635-645
    CrossrefPubMedGoogle Scholar
  • 2 Schimmelmann BG, Conus P, Cotton S. et al . Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients.  Schizophr Res. 2007;  95 1-8
    Google Scholar
  • 3 Lay B, Blanz B, Hartmann M. et al . The psychosocial outcome of adolescent-onset schizophrenia: a 12-year follow-up.  Schizophr Bull. 2000;  26 801-816
    PubMedGoogle Scholar
  • 4 Fleischhaker C, Schulz E, Tepper K. et al . Long-term course of adolescent schizophrenia.  Schizophr Bull. 2005;  31 769-780
    CrossrefPubMedGoogle Scholar
  • 5 Ballageer T, Malla A, Manchanda R. et al . Is adolescent-onset first-episode psychosis different from adult onset?.  J Am Acad Child Adolesc Psychiatry. 2005;  44 782-789
    Google Scholar
  • 6 Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up.  Psychiatry Res. 2005;  133 35-43
    CrossrefPubMedGoogle Scholar
  • 7 Fraguas D, Correll CU, Merchan-Naranjo J. et al . Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons.  Eur Neuropsychopharmacol. 2010;  Aug 9
    PubMedGoogle Scholar
  • 8 Moore TA, Buchanan RW, Buckley PF. et al . The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.  J Clin Psychiatry. 2007;  68 1751-1762
    CrossrefPubMedGoogle Scholar
  • 9 Kane JM, Leucht S, Carpenter D. et al . The expert consensus guideline series – Optimizing pharmacologic treatment of psychotic disorders.  J Clin Psychiatry. 2003;  64 (Suppl. 12) 4-100
    CrossrefPubMedGoogle Scholar
  • 10 van OSJ, Kapur S. Schizophrenia.  Lancet. 2009;  374 (9690) 635-645
    CrossrefPubMedGoogle Scholar
  • 11 Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? [Review].  Psychopharmacology. 2000;  148 3-15
    CrossrefPubMedGoogle Scholar
  • 12 Armenteros JL, Davies M. Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis.  Eur Child Adolesc Psychiatry. 2006;  15 141-148
    CrossrefPubMedGoogle Scholar
  • 13 Sikich L, Frazier JA, McClellan J. et al . Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.  Am J Psychiatry. 2008;  165 1420-1431
    Google Scholar
  • 14 Vitiello B, Correll C, Zwieten-Boot B. et al . Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns.  Eur Neuropsychopharmacol. 2009;  May 23
    Google Scholar
  • 15 Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients.  Eur Neuropsychopharmacol. 2004;  (S 04) S471-S479
    PubMedGoogle Scholar
  • 16 Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.  J Clin Psychiatry. 2008;  69 (S 04) 21-25
    CrossrefPubMedGoogle Scholar
  • 17 Lieberman JA, Perkins D, Belger A. et al . The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches.  Biol Psychiatry. 2001;  50 884-897
    CrossrefPubMedGoogle Scholar
  • 18 Kumra S, Oberstar JV, Sikich L. et al . Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.  Schizophr Bull. 2008;  34 60-71
    CrossrefPubMedGoogle Scholar
  • 19 Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.  J Clin Psychiatry. 2008;  69 (S 04) 26-36
    CrossrefPubMedGoogle Scholar
  • 20 McConville BJ, Sorter MT. Treatment challenger and safety considerations for antipsychotic use in chidren and adolescents with psychoses.  J Clin Psychiatry. 2004;  65 (Suppl. 6) 20-29
    PubMedGoogle Scholar
  • 21 Mattai AK, Hill JL, Lenroot RK. Treatment of early-onset schizophrenia.  Curr Opin Psychiatry. 2010;  23 304-310
    CrossrefPubMedGoogle Scholar
  • 22 Small JG, Hirsch SR, Arvanitis LA. et al . Seroquel Study Group. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo.  Arch Gen Psychiatry. 1997;  54 549-557
    CrossrefPubMedGoogle Scholar
  • 23 Adityanjee MD, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia.  J Clin Psychiatry. 2002;  63 (S 13) 32-38
    PubMedGoogle Scholar
  • 24 Martinotti G, Andreoli S, Di Nicola M. et al . Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics.  Hum Psychopharmacol. 2008;  23 417-424
    CrossrefPubMedGoogle Scholar
  • 25 Vaishnavi S, Alamy S, Zhang W. et al . Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.  Prog Neuropsychopharmacol Biol Psychiatry. 2007;  31 1464-1469
    CrossrefPubMedGoogle Scholar
  • 26 Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing.  J Clin Psychiatry. 2002;  63 (S 13) 5-11
    PubMedGoogle Scholar
  • 27 Kapur S, Zipursky R, Jones C. et al . A positron emission tomography study of quetiapine in schizophrenia – a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.  Arch Gen Psychiatry. 2000;  57 553-559
    CrossrefPubMedGoogle Scholar
  • 28 Gefvert O, Lundberg T, Wieselgren IM. et al . D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study.  Eur Neuropsychopharmacol. 2001;  11 105-110
    CrossrefPubMedGoogle Scholar
  • 29 DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine – an atypical antipsychotic.  Clin Pharmacokinet. 2001;  40 509-522
    CrossrefPubMedGoogle Scholar
  • 30 Winter HR, Earley WR, Hamer-Maansson JE. et al . Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.  J Child Adolesc Psychopharmacol. 2008;  18 81-98
    CrossrefPubMedGoogle Scholar
  • 31 Jensen NH, Rodriguiz RM, Caron MG. et al . N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.  Neuropsychopharmacology. 2008;  33 2303-2312
    CrossrefPubMedGoogle Scholar
  • 32 Findling RL. Use of quetiapine in children and adolescents.  J Clin Psychiatry. 2002;  63 (S 13) 27-31
    PubMedGoogle Scholar
  • 33 Cheng-Shannon J, McGough JJ, Pataki C. et al . Second-generation antipsychotic medications in children and adolescents.  J Child Adolesc Psychopharmacol. 2004;  14 372-394
    CrossrefPubMedGoogle Scholar
  • 34 Beer F, Heinrich H, Springer S. et al . Quetiapine in the treatment of psychotic adolescents: a case series of 23 patients with severe early onset psychosis.  World J Biol Psychiatry. 2007;  8 38-41
    CrossrefPubMedGoogle Scholar
  • 35 Schimmelmann BG, Mehler-Wex C, Lambert M. et al . A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.  J Child Adolesc Psychopharmacol. 2007;  17 768-778
    CrossrefPubMedGoogle Scholar
  • 36 Bishop JR, Pavuluri MN. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia.  Neuropsychiatr Dis Treat. 2008;  4 55-68
    PubMedGoogle Scholar
  • 37 Coukell AJ, Spencer CM, Benfield P. Amisulpride – A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia.  CNS Drugs. 1996;  6 237-256
    CrossrefPubMedGoogle Scholar
  • 38 Roke Y, van Harten PN, Boot AM. et al . Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects.  J Child Adolesc Psychopharmacol. 2009;  19 403-414
    CrossrefPubMedGoogle Scholar
  • 39 Castro-Fornieles J, Parellada M, Soutullo CA. et al . Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.  J Child Adolesc Psychopharmacol. 2008;  18 327-336
    CrossrefPubMedGoogle Scholar
  • 40 Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review.  J Child Adolesc Psychopharmacol. 2007;  17 647-656
    CrossrefPubMedGoogle Scholar
  • 41 Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.  J Clin Psychiatry. 2008;  69 1157-1165
    CrossrefPubMedGoogle Scholar
  • 42 Jerrell JM, Hwang TL, Livingston TS. Neurological adverse events associated with antipsychotic treatment in children and adolescents.  J Child Neurol. 2008;  23 1392-1399
    CrossrefPubMedGoogle Scholar
  • 43 Kuehn BM. FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.  JAMA. 2009;  302 833-834
    CrossrefPubMedGoogle Scholar
  • 44 Greenspan A, Gharabawi G, Kwentus J. Thyroid dysfunction during treatment with atypical antipsychotics.  J Clin Psychiatry. 2005;  66 1334-1335
    PubMedGoogle Scholar
  • 45 Potkin SG, Gharabawi GM, Greenspan AJ. et al . A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.  Schizophr Res. 2006;  85 254-265
    CrossrefPubMedGoogle Scholar
  • 46 Kontaxakis VP, Karaiskos D, Havaki-Kontaxaki BJ. et al . Can quetiapine-induced hypothyroidism be reversible without quetiapine discontinuation?.  Clin Neuropharmacol. 2009;  32 295-296
    CrossrefPubMedGoogle Scholar
  • 47 Fraguas D, Merchan-Naranjo J, Laita P. et al . Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.  J Clin Psychiatry. 2008;  69 1166-1175
    CrossrefPubMedGoogle Scholar
  • 48 Simon V, van WR, de HM. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.  J Clin Psychiatry. 2009;  70 1041-1050
    CrossrefPubMedGoogle Scholar
  • 49 Bolognini M, Plancherel B, Laget J. et al . Evaluation of the adolescent drug abuse diagnosis instrument in a Swiss sample of drug abusers.  Addiction. 2001;  96 1477-1484
    CrossrefPubMedGoogle Scholar
  • 50 Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): rationale and standardisation.  Br J Psychiatry. 1989;  155 (suppl 7) 59-65
    PubMedGoogle Scholar
  • 51 Guy W. ECDEU Assessment Manual for Psychopharmacology.. Washington, DC: Department of Health, Education and Welfare; 1976
    Google Scholar
  • 52 Simpson GM, Angus JW. A rating scale for extrapyramidal side effects.  Acta Psychiatr Scand Suppl. 1970;  212 11-19
    PubMedGoogle Scholar
  • 53 Barnes TR. A rating scale for drug-induced akathisia.  Br J Psychiatry. 1989;  154 672-676
    CrossrefPubMedGoogle Scholar
  • 54 Le Bloc’h Y, Baumann P, Stigler M. et al . Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study.  Int J Psychiatry Clin Pract. 2007;  11 123-128
    CrossrefPubMedGoogle Scholar
  • 55 Cole TJ. A chart to link child centiles of body mass index, weight and height.  Eur J Clin Nutr. 2002;  56 1194-1199
    CrossrefPubMedGoogle Scholar
  • 56 Farpour-Lambert N, L’Allemand D, Laimbacher J. Définition, diagnostic et indications thérapeutiques de la surcharge pondérale de l’enfant et de l’adolescent.  Paediatrica. 2006;  17 19-24
    PubMedGoogle Scholar
  • 57 Berger GE, Proffitt TM, McConchie M. et al . Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.  J Clin Psychiatry. 2008;  69 1702-1714
    CrossrefPubMedGoogle Scholar
  • 58 Haas M, Unis AS, Armenteros J. et al . A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.  J Child Adolesc Psychopharmacol. 2009;  19 611-621
    CrossrefPubMedGoogle Scholar
  • 59 Findling RL, Robb A, Nyilas M. et al . A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.  Am J Psychiatry. 2008;  165 1432-1441
    CrossrefPubMedGoogle Scholar
  • 60 Takahashi H, Oshimo T, Ishigooka J. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial.  Clin Neuropharmacol. 2009;  32 149-150
    CrossrefPubMedGoogle Scholar
  • 61 Lee HY, Ham BJ, Kang RH. et al . Trial of aripiprazole in the treatment of first-episode schizophrenia.  Psychiatry Clin Neurosci. 2010;  64 38-43
    CrossrefPubMedGoogle Scholar
  • 62 Larsen TK, Melle I, Auestad B. et al . Substance abuse in first-episode non-affective psychosis.  Schizophr Res. 2006;  88 55-62
    CrossrefPubMedGoogle Scholar
  • 63 Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study.  Acta Psychiatr Scand. 2007;  115 304-309
    CrossrefPubMedGoogle Scholar
  • 64 McConville BJ, Arvanitis LA, Thyrum PT. et al . Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.  J Clin Psychiatry. 2000;  61 252-260
    CrossrefPubMedGoogle Scholar
  • 65 Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.  Am J Psychiatry. 1999;  156 876-884
    PubMedGoogle Scholar
  • 66 Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis.  Am J Psychiatry. 2001;  158 360-369
    Google Scholar
  • 67 Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder.  J Child Adolesc Psychopharmacol. 2008;  18 140-156
    CrossrefPubMedGoogle Scholar
  • 68 Duffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine.  BMC Psychiatry. 2009;  9 4
    CrossrefPubMedGoogle Scholar
  • 69 Gerlach M, Hunnerkopf R, Rothenhofer S. et al . Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders.  Pharmacopsychiatry. 2007;  40 72-76
    Article in Thieme ConnectPubMedGoogle Scholar
  • 70 Hasselstrøm J, Linnet K. Quetiapine serum concentrations in psychiatric patients – The influence of comedication.  Ther Drug Monit. 2004;  26 486-491
    CrossrefPubMedGoogle Scholar
  • 71 Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M. et al . Large intraindividual variability of olanzapine serum concentrations in adolescent patients.  Ther Drug Monit. 2008;  3 108-112
    PubMedGoogle Scholar
  • 72 Aichhorn W, Marksteiner J, Walch T. et al . Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations.  Int Clin Psychopharmacol. 2006;  21 81-85
    CrossrefPubMedGoogle Scholar
  • 73 Pichini S, Papaseit E, Joya X. et al . Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics.  Ther Drug Monit. 2009;  31 283-318
    CrossrefPubMedGoogle Scholar
  • 74 Mehler-Wex C, Kolch M, Kirchheiner J. et al . Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy.  Child Adolesc Psychiatry Ment Health. 2009;  3 14
    CrossrefPubMedGoogle Scholar

Correspondence

L. HolzerMD 

Service Universitaire de

Psychiatrie de l'Enfant et de

l' Adolescent (SUPEA)

Centre Thérapeutique de Jour

pour Adolescents (CTJA)

Av. de Beaumont 48

1012 Lausanne

Switzerland

Phone: +41/21/314 1730

Fax: +41/21/314 1735

Email: laurent.holzer@chuv.ch

      >